Goldman Sachs Comment on Perrigo's (PRGO) Omega Deal and Quarterly Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
Go back to Goldman Sachs Comment on Perrigo's (PRGO) Omega Deal and Quarterly Results
November 6, 2014 6:33 AM EST
Perrigo (NYSE: PRGO) reported Q1 EPS of $1.40, $0.04 worse than the analyst estimate of $1.44. Revenue for the quarter came in at $951.5 million versus the consensus estimate of $997.9 million.
For earnings history and earnings-related data on Perrigo (PRGO) click here.
...
More
November 6, 2014 6:28 AM EST
Perrigo (NYSE: PRGO) and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for 3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for 2.48 billion and the assumption of 1.1 billion in debt. The transaction, funded through a combination of cash, debt, and equity, will enhance Perrigo's leading OTC product offering and expand its distribution through Omega's strong established platform.
"The combination of these two great companies accelerates Perrigo's international growth... More
